Form 4: Voyager Therapeutics Director George A. Scangos Acquires 24,000 Stock Options

Director George A. Scangos acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Summary

• On June 5, 2024, George A. Scangos, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options.
• The options have an exercise price of $8.70.
• These options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The options vest upon the earlier of one year from the grant date or the date of the next annual meeting of stockholders, contingent on continued service as a director.
• Following the transaction, Scangos directly owns 24,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock option grant) that is part of director compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Voyager Therapeutics' director compensation to that of similar-sized gene therapy companies like Sarepta Therapeutics or Bluebird Bio would provide a better understanding of whether this grant is in line with industry standards.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates